Genprex to Present at Upcoming Investor and Industry Conferences
AUSTIN,Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 1, 2018--Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that the management team will present at the following upcoming investor and industry conferences:
Event: The MicroCap Conference Date: October 2, 2018 Time: 12:00 PM EDT Location: New York, NY Presenter: Rodney Varner, Chairman and CEO
Event: BIO Investor Forum Date: October 18, 2018 Time: 9:30 AM PDT Location: San Francisco, CA Presenter: Dr. Julien Pham, President and COO
About Genprex™, Inc. Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181001005321/en/
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS TEXAS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS ONCOLOGY OTHER HEALTH
SOURCE: Genprex, Inc.
Copyright Business Wire 2018.
PUB: 10/01/2018 08:00 AM/DISC: 10/01/2018 08:01 AM